Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Source: 
Fierce Biotech
snippet: 

Sanofi has revised the dosing scheme in its phase 3 assessment of RNAi drug fitusiran to reduce the risk of vascular thrombotic events in hemophilia patients. The revised scheme is intended to prevent the low levels of clot inhibitor antithrombin (AT) associated with vascular thrombotic events.